World Investment Advisors Sells 2,955 Shares of Zoetis Inc. $ZTS

World Investment Advisors reduced its stake in Zoetis Inc. (NYSE:ZTS) by 9.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,757 shares of the company’s stock after selling 2,955 shares during the quarter. World Investment Advisors’ holdings in Zoetis were worth $4,641,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Nuveen LLC purchased a new stake in shares of Zoetis in the 1st quarter worth $616,375,000. Mackenzie Financial Corp increased its holdings in Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after buying an additional 1,782,110 shares during the period. Polen Capital Management LLC grew its stake in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. Amundi lifted its position in Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after purchasing an additional 846,909 shares during the period. Finally, OVERSEA CHINESE BANKING Corp Ltd grew its stake in Zoetis by 475.9% during the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after acquiring an additional 743,926 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 1.0%

ZTS opened at $143.97 on Thursday. The company has a market capitalization of $63.80 billion, a P/E ratio of 24.78, a P/E/G ratio of 2.34 and a beta of 0.90. The firm’s fifty day moving average price is $147.63 and its two-hundred day moving average price is $153.48. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $183.81. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s payout ratio is currently 34.42%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZTS. UBS Group reduced their target price on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a report on Monday, October 20th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler boosted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.